New blood test registry aims to improve neuroendocrine tumor care
NCT ID NCT02270567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry is collecting blood samples and health data from 400 people with neuroendocrine tumors. The goal is to see if a new blood test called NETest can help detect tumor activity and predict disease progression. Participants include patients before and after surgery, those on watchful waiting, and those receiving various treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NETest blood test
- What this could lead to
- If successful, this registry could help validate a simple blood test to detect neuroendocrine tumor activity and guide treatment decisions.
- What could go wrong
- This is an observational registry, not a treatment trial. It will not directly test whether the blood test improves patient outcomes, and results may take years to analyze.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 400 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Feb 2015
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a histologically confirmed diagnosis of a neuroendocrine tumor undergoing treatment and follow-up evaluation. This includes real-world patients as well as patients included in investigator-initiated clinical studies (IICS) e.g., PRRT or curative surgery.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Gastroenteropancreatic neuroendocrine tumor * Bronchopulmonary neuroendocrine tumor * Gastroenteropancreatic neuroendocrine carcinoma * Pre- and post-surgical patients * Watch \& Wait/no treatment * Treatment including somatostatin analogues, PRRT, targeted therapies. * Patient provides informed consent Exclusion Criteria: * N/A
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bronchopulmonary neuroendocrine tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Wren Laboratories
Branford, Connecticut, 06405, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Swiss registry aims to map rare neuroendocrine tumors
- Can a Two-Drug chemo combo outsmart resistant tumors?
- Can armored CAR t cells take down Hard-to-Treat neuroendocrine cancers?
- A simple blood draw could spot tumor relapse before scans do
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing